Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

MARTINA PORTER

NPI
1871931618
CMS profile
1389201
Location
JAMAICA PLAIN, MA

General Payments · PY2018–2024

$141,664.64

  • Reported across 95 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$35,909.74

35 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Incyte Corporation $14,900.97 15
UCB, Inc. $12,676.25 7
NOVARTIS PHARMACEUTICALS CORPORATION $4,030.32 6
UCB SA $2,925.00 1
Boehringer Ingelheim International GmbH $1,051.28 3
ABBVIE INC. $325.92 3

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $3,417.75 16
PY2019 $3,514.80 2
PY2020 $25,187.44 2
PY2021 $16,480.00 1
PY2022 $22,832.58 19
PY2023 $34,322.33 20
PY2024 $35,909.74 35

Payment records · PY2024 (35)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
ABBVIE INC. $10.47 03/14/2024 Food and Beverage Undisputed 01/23/2026 1105296496 CMS
ABBVIE INC. $302.96 04/11/2024 Consulting Fee Undisputed 01/23/2026 1105296501 CMS
ABBVIE INC. $12.49 09/27/2024 Food and Beverage Undisputed 01/23/2026 1105296505 CMS
Boehringer Ingelheim International GmbH $356.33 04/11/2024 Consulting Fee Undisputed 01/23/2026 1118206573 CMS
Boehringer Ingelheim International GmbH $678.93 05/20/2024 Consulting Fee Undisputed 01/23/2026 1118206577 CMS
Boehringer Ingelheim International GmbH $16.02 09/27/2024 Food and Beverage Undisputed 01/23/2026 1118206581 CMS
Incyte Corporation $3,750.00 04/09/2024 Consulting Fee Undisputed 01/23/2026 1141172699 CMS
Incyte Corporation $272.67 05/20/2024 Consulting Fee Undisputed 01/23/2026 1141197113 CMS
Incyte Corporation $6.14 09/27/2024 Food and Beverage Undisputed 01/23/2026 1141248132 CMS
Incyte Corporation $307.00 10/03/2024 Travel and Lodging Undisputed 01/23/2026 1141266997 CMS
Incyte Corporation $163.10 10/03/2024 Travel and Lodging Undisputed 01/23/2026 1141266999 CMS
Incyte Corporation $23.95 10/04/2024 Food and Beverage Undisputed 01/23/2026 1141191165 CMS
Incyte Corporation $124.50 10/04/2024 Travel and Lodging Undisputed 01/23/2026 1141191167 CMS
Incyte Corporation $198.47 10/04/2024 Travel and Lodging Undisputed 01/23/2026 1141191169 CMS
Incyte Corporation $8,062.50 10/04/2024 Consulting Fee Undisputed 01/23/2026 1141196857 CMS
Incyte Corporation $7.95 10/04/2024 Food and Beverage Undisputed 01/23/2026 1141196859 CMS
Incyte Corporation $10.75 10/04/2024 Food and Beverage Undisputed 01/23/2026 1141196861 CMS
Incyte Corporation $240.90 10/04/2024 Travel and Lodging Undisputed 01/23/2026 1141239147 CMS
Incyte Corporation $99.60 10/04/2024 Travel and Lodging Undisputed 01/23/2026 1141292742 CMS
Incyte Corporation $133.44 11/04/2024 Consulting Fee Undisputed 01/23/2026 1141196599 CMS
Incyte Corporation $1,500.00 12/18/2024 Consulting Fee Undisputed 01/23/2026 1141172079 CMS
Novartis Pharmaceuticals Corporation $37.87 02/17/2024 Food and Beverage Undisputed 01/23/2026 1087157117 CMS
Novartis Pharmaceuticals Corporation $328.36 04/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 1087157167 CMS
Novartis Pharmaceuticals Corporation $15.26 09/27/2024 Food and Beverage Undisputed 01/23/2026 1087157169 CMS
Novartis Pharmaceuticals Corporation $23.83 11/03/2024 Food and Beverage Undisputed 01/23/2026 1087157163 CMS
Novartis Pharmaceuticals Corporation $2,025.00 11/03/2024 Consulting Fee Undisputed 01/23/2026 1087157165 CMS
Novartis Pharmaceuticals Corporation $1,600.00 11/29/2024 Consulting Fee Undisputed 01/23/2026 1087157161 CMS
UCB SA $2,925.00 08/02/2024 Consulting Fee Undisputed 01/23/2026 1113950901 CMS
UCB, Inc. $32.26 03/07/2024 Food and Beverage Undisputed 01/23/2026 1143057830 CMS
UCB, Inc. $19.23 05/19/2024 Food and Beverage Undisputed 01/23/2026 1143057832 CMS
UCB, Inc. $49.99 05/19/2024 Food and Beverage Undisputed 01/23/2026 1143057834 CMS
UCB, Inc. $1,950.00 06/11/2024 Consulting Fee Undisputed 01/23/2026 1143057836 CMS
UCB, Inc. $9,315.00 07/02/2024 Consulting Fee Undisputed 01/23/2026 1143057838 CMS
UCB, Inc. $9.77 09/27/2024 Food and Beverage Undisputed 01/23/2026 1143057840 CMS
UCB, Inc. $1,300.00 10/30/2024 Consulting Fee Undisputed 01/23/2026 1143057842 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.